Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 3/20 | 0.41 |
| ▸ | CHUK | O15111 | 2/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | GLRA3 | O75311 | 2/20 | 0.37 |
| ▸ | GLRB | P48167 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17455970 | 0.94 | CHRM1 (0.43) | CHRM1IKBKBCHUKPSEN1PSEN2 | |
| SCHEMBL17456035 | 0.88 | CHRM1 (0.38) | CHRM1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21238823 | 0.84 | TDO2 (0.42) | IKBKBCHUKGLRA3GLRBTDO2 | |
| SCHEMBL17455989 | 0.83 | IKBKB (0.52) | IKBKBCHUKTDO2PTGDRCYP1A2 | |
| SCHEMBL17455926 | 0.82 | CHRM1 (0.38) | CHRM1IKBKBCHUKPSEN1PSEN2 | |
| SCHEMBL17455942 | 0.81 | IKBKB (0.42) | IKBKBCHUKTDO2CYP1A2 | |
| SCHEMBL17455945 | 0.81 | CHRM1 (0.43) | CHRM1IKBKBCHUKMCHR1HTR2C | |
| SCHEMBL17456027 | 0.78 | CHRM1 (0.46) | CHRM1 | |
| SCHEMBL17455929 | 0.78 | CHRM1 (0.40) | CHRM1IKBKBCHUKMCHR1HTR2C | |
| SCHEMBL17455951 | 0.76 | CHRM1 (0.41) | CHRM1IKBKBCHUKMCHR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| EP-2982666-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | CHRM1 519/4885IKBKB 2723/4885CHUK 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.